Related references
Note: Only part of the references are listed.Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas
Roberto Wuerth et al.
MOLECULAR NEUROBIOLOGY (2017)
Survival regulation of leukemia stem cells
Yiguo Hu et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy
Zheng Chen et al.
CLINICAL CANCER RESEARCH (2016)
BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia
S-S Chen et al.
LEUKEMIA (2016)
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway
Manoj K. Kashyap et al.
ONCOTARGET (2016)
Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome
Astrid Olsnes Kittang et al.
ONCOIMMUNOLOGY (2016)
Acute Myeloid Leukemia: Past, Present, and Prospects for the Future
Nicholas J. Short et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Trends in Clinical Investigation for Myelodysplastic Syndromes
Thomas Prebet et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Preparation and characterization of a new monoclonal antibody against CXCR4 using lentivirus vector
Xinyi Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4
Katherine Griffiths et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Requirement of CXCL12-CXCR7 signaling for CD20- CD138- double-negative population in lymphoplasmacytic lymphoma
Naoki Wada et al.
LABORATORY INVESTIGATION (2016)
A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells
Matthieu Broussas et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
Sheng-Bin Peng et al.
PLOS ONE (2016)
Pancreatic cancer stem cell markers and exosomes - the incentive push
Sarah Heiler et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Immune Complexes in Juvenile Idiopathic Arthritis
Terry L. Moore
FRONTIERS IN IMMUNOLOGY (2016)
The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
Linn Reinholdt et al.
BIOMARKER RESEARCH (2016)
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy
Byung-Sik Cho et al.
BLOOD (2015)
T-ALL: Home Is where the CXCL12 Is
Charles E. de Bock et al.
CANCER CELL (2015)
CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance
Lauren A. Pitt et al.
CANCER CELL (2015)
Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities
Koen Schepers et al.
CELL STEM CELL (2015)
CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction
Wan-Tseng Hsu et al.
CELL TRANSPLANTATION (2015)
Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells
Mohammed I. Khan et al.
STEM CELL RESEARCH & THERAPY (2015)
Role of Microenvironment in Resistance to Therapy in AML
Yoko Tabe et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
CXCL12/SDF-1 and CXCR4
Takashi Nagasawa
FRONTIERS IN IMMUNOLOGY (2015)
CXCR4/CXCR7 Molecular Involvement in Neuronal and Neural Progenitor Migration: Focus in CNS Repair
Jose Joaquin Merino et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2015)
Expression and functional roles of the chemokine receptor CXCR7 in acute myeloid leukemia cells
Ha-Yon Kim et al.
BLOOD RESEARCH (2015)
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization
Julia Hoellenriegel et al.
BLOOD (2014)
The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
Amnon Peled et al.
CLINICAL CANCER RESEARCH (2014)
A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky et al.
CLINICAL CANCER RESEARCH (2014)
Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Won-Tak Choi et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2014)
CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes
Shiho Abe-Suzuki et al.
LABORATORY INVESTIGATION (2014)
Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
Katia Beider et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies
Jan A. Burger et al.
SEMINARS IN CANCER BIOLOGY (2014)
Glycosylation of TRPM4 and TRPM5 channels: molecular determinants and functional aspects
Ninda Syam et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2014)
Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition
Edward Allan R. Sison et al.
ONCOTARGET (2014)
International Union of Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors
Francoise Bachelerie et al.
PHARMACOLOGICAL REVIEWS (2014)
Minimalist Hybrid Ligand/Receptor-Based Pharmacophore Model for CXCR4 Applied to a Small-Library of Marine Natural Products Led to the Identification of Phidianidine A as a New CXCR4 Ligand Exhibiting Antagonist Activity
Rosa Maria Vitale et al.
ACS CHEMICAL BIOLOGY (2013)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
HIF-2α Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress
Kevin Rouault-Pierre et al.
CELL STEM CELL (2013)
BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies
Michelle R. Kuhne et al.
CLINICAL CANCER RESEARCH (2013)
Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12
Cuiling Zhong et al.
CLINICAL CANCER RESEARCH (2013)
Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
Katia Beider et al.
CLINICAL CANCER RESEARCH (2013)
The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells
Laia Rosich et al.
HAEMATOLOGICA (2013)
Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growth in Vivo
David Maussang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
D. Karpova et al.
LEUKEMIA (2013)
CXCL12 in early mesenchymal progenitors is. required for haematopoietic stem-cell maintenance
Adam Greenbaum et al.
NATURE (2013)
Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity
Monica Gatti et al.
TOXICOLOGY (2013)
Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia
Amnon Peled et al.
THERANOSTICS (2013)
The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitor
Renee M. Mosi et al.
BIOCHEMICAL PHARMACOLOGY (2012)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2012)
AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments
Basile Stamatopoulos et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Development of a Unique Small Molecule Modulator of CXCR4
Zhongxing Liang et al.
PLOS ONE (2012)
CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Filomena de Nigris et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2012)
Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib
Davorka Messmer et al.
BLOOD (2011)
Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists
Sameer P. Kawatkar et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2011)
CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth
Katia Beider et al.
EXPERIMENTAL HEMATOLOGY (2011)
Chemokines and chemokine receptors: New actors in neuroendocrine regulations
William Rostene et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2011)
An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease
Paolo Giannoni et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration
Fabien M. Decaillot et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia
Ching-Hon Pui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting
Marina Y. Konopleva et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in
Armin Ehninger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature
Roberto Wuerth et al.
JOURNAL OF NEUROIMMUNOLOGY (2011)
Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
R. Parameswaran et al.
LEUKEMIA (2011)
MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias
I. Spinello et al.
BLOOD CANCER JOURNAL (2011)
The Peptidomimetic CXCR4 Antagonist TC14012 Recruits β-Arrestin to CXCR7 ROLES OF RECEPTOR DOMAINS
Stephanie Gravel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
CXCR7 Protein Is Not Expressed on Human or Mouse Leukocytes
Robert D. Berahovich et al.
JOURNAL OF IMMUNOLOGY (2010)
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
F. Fei et al.
LEUKEMIA (2010)
CXCR7 Functions as a Scavenger for CXCL12 and CXCL11
Ulrike Naumann et al.
PLOS ONE (2010)
β-arrestin- but not G protein-mediated signaling by the decoy receptor CXCR7
Sudarshan Rajagopal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells
Sven Jahnichen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
Bruno Nervi et al.
BLOOD (2009)
CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling
Angelique Levoye et al.
BLOOD (2009)
Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4-Tropic HIV Type 1
Graeme Moyle et al.
CLINICAL INFECTIOUS DISEASES (2009)
Recent patents regarding the discovery of small molecule CXCR4 antagonists
Cara A. Mosley et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma
John F. DiPersio et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells
Joseph Kwong et al.
MOLECULAR CANCER THERAPEUTICS (2009)
AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties
Irina Kalatskaya et al.
MOLECULAR PHARMACOLOGY (2009)
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
J. A. Burger et al.
LEUKEMIA (2009)
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL(+) cell to Imatinib and Nilotinib
Falk Dillmann et al.
LEUKEMIA & LYMPHOMA (2009)
Functional diversity of SDF-1 splicing variants
Miroslaw Janowski
CELL ADHESION & MIGRATION (2009)
A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma
Amanda Cashen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Control of chemokine-guided cell migration by ligand sequestration
Bijan Boldajipour et al.
CELL (2008)
Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas
Federica Barbieri et al.
CLINICAL CANCER RESEARCH (2008)
The design, structures and therapeutic potential of protein epitope mimetics
John A. Robinson et al.
DRUG DISCOVERY TODAY (2008)
A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells
Tanja Nicole Hartmann et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
Linhua Jin et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells
Angela Colmone et al.
SCIENCE (2008)
Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases
Su Young Kim et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
被撤回的出版物: The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer (Retracted article. See vol. 298, 2022)
Jianhua Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature
Zhenhua Miao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7
Frederic Sierro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells
Oystein Bruserud et al.
HAEMATOLOGICA (2007)
Niche-to-niche migration of bone-marrow-derived cells
Rosandra N. Kaplan et al.
TRENDS IN MOLECULAR MEDICINE (2007)
CXCR4 and SDF1 expression in human meningiomas: A proliferative role in tumoral meningothelial cells in vitro
Adriana Bajetto et al.
NEURO-ONCOLOGY (2007)
The many facets of SDF-1 alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells
Anne Faber et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2007)
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas
Navid Redjal et al.
CLINICAL CANCER RESEARCH (2006)
Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: Role of CXCR4 and SDF1 in glioma cell proliferation and migration
Adriana Bajetto et al.
NEUROCHEMISTRY INTERNATIONAL (2006)
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development
Jennifer M. Burns et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Identification and expression of novel isoforms of human stromal cell-derived factor 1
Lan Yu et al.
GENE (2006)
AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor
S Hatse et al.
BIOCHEMICAL PHARMACOLOGY (2005)
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors
JB Rubin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The bicyclam AMD3 100 story
E De Clercq
NATURE REVIEWS DRUG DISCOVERY (2003)
β-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation
Y Sun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C axe weak partial agonists
WB Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Stromal cell-derived factor 1 is secreted by meningeal cells and acts as chemotactic factor on neuronal stem cells of the cerebellar external granular layer
K Reiss et al.
NEUROSCIENCE (2002)
High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia
R Crazzolara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1α:: implications for development of selective CXCR4 antagonists
SK Gupta et al.
IMMUNOLOGY LETTERS (2001)
Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140
H Tamamura et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Involvement of chemokine receptors in breast cancer metastasis
A Müller et al.
NATURE (2001)
β-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between β-arrestin and CXCR4
ZJ Cheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
